Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination With VTX 2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Conditions
Interventions
VTX-2337
Carboplatin
+3 more
Locations
53
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Tower Hematology Oncology Medical Group
Beverly Hills, California, United States
California Cancer Associates for Research and Excellence (CCARE)
Escondido, California, United States
University of California San Diego Moores Cancer Center
La Jolla, California, United States
University of California Norris Comprehensive Cancer Center
Los Angeles, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Start Date
October 14, 2013
Primary Completion Date
April 13, 2016
Completion Date
September 19, 2016
Last Updated
October 29, 2019
NCT03485209
NCT02296684
NCT03509012
NCT02383966
NCT02585973
NCT02822482
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions